Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.44 |
| ▸ | SKP1 | P63208 | 2/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29574323 | 0.87 | CKS1B (0.56) | CKS1BSKP1SKP2GPR119MAP4K4 | |
| SCHEMBL441495 | 0.87 | CKS1B (0.56) | CKS1BSKP1SKP2GPR119MAP4K4 | |
| SCHEMBL1481924 | 0.83 | CKS1B (0.59) | CKS1BSKP1SKP2GPR119PDE10A | |
| SCHEMBL15401386 | 0.82 | GRIN2D (0.41) | PDE10ATGM2ALDH1A1 | |
| SCHEMBL31383652 | 0.81 | MAP4K4 (0.58) | GPR119MAP4K4 | |
| SCHEMBL15401349 | 0.81 | CKS1B (0.45) | CKS1BSKP1SKP2GPR119MAP4K4 | |
| SCHEMBL31383595 | 0.81 | MAP4K4 (0.58) | GPR119MAP4K4 | |
| SCHEMBL30112375 | 0.80 | AKR1C3 (0.47) | CKS1BSKP1SKP2GPR119PDE10A | |
| SCHEMBL29197774 | 0.80 | AKR1C3 (0.47) | CKS1BSKP1SKP2GPR119PDE10A | |
| SCHEMBL15401487 | 0.80 | PDE4B (0.42) | GPR119ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867232-B1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2018-08-08 | — | — | EP | disclosed |
| EP-2867232-B1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2018-08-08 | — | — | EP | disclosed |
| US-9434725-B2 | 5-azaindazole compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-06 | — | — | US | disclosed |
| US-9434725-B2 | 5-azaindazole compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-06 | — | — | US | disclosed |
| US-9434725-B2 | 5-azaindazole compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-06 | — | — | US | disclosed |
| EP-2867232-A1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014001377-A1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| US-20140005168-A1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | GENENTECH,INC. | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005168-A1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | CKS1B 177/4885SKP1 1194/4885SKP2 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.